US Stock MarketDetailed Quotes

PRRUF IMMUTEP LTD

Watchlist
  • 0.204
  • 0.0000.00%
15min DelayClose Nov 12 16:00 ET
296.66MMarket Cap-9.27P/E (TTM)

About IMMUTEP LTD Company

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Company Profile

SymbolPRRUF
Company NameIMMUTEP LTD
Listing DateApr 16, 2012
Founded1987
CEOMr. Marc Voigt
MarketPink Market
Employees44
Fiscal Year Ends06-30
AddressAustralia Square,264 George Street,Level 32, Suite 32.07
CitySydney
ProvinceNew South Wales (NSW)
CountryAustralia
Zip Code2000
Phone61-2-8315-7003
Websitehttp://www.immutep.com

Company Executives

  • Name
  • Position
  • Salary
  • Marc Voigt
  • Director, Chief Executive Officer and Chief Financial Officer
  • 1.06M
  • Deanne Miller
  • Chief Operating Officer, General Counsel and Company Secretary
  • 565.23K
  • Dr. Florian Vogl, M.D.,PhD
  • Chief Medical Officer
  • 955.82K
  • Professor Dr. Frederic Triebel, M.D.
  • Executive Director and Chief Scientific Officer
  • 864.44K
  • Dr. Russell J. Howard, PhD
  • Chairman of the Board
  • 222.02K
  • Pete A. Meyers
  • Deputy Chairman of the Board
  • 138.71K
  • Lis Boyce
  • Independent Director
  • 144.76K
Heat List
US
Overall
Symbol
Price
% Chg

No Data